The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Ngiow, Shin Foong ^a,b   von Scheidt, Bianca ^a   Möller, Andreas ^a,b   Smyth, Mark J ^a,b   Teng, Michele W L ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoimmunity; Effector; Immune modulation; Suppression; Treg; Tumor immunity

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; GAMMA INTERFERON; GRANZYME B; KI 67 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HOST CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MELANOMA; MOLECULAR DYNAMICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROLONGED IMMUNE RESPONSE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNE SYSTEM INTERACTION; TUMOR IMMUNITY; VITILIGO;

EID: 84886943899     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23036     Document Type: Article

References (25)

1. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96; PMID:17134371; http://dx.doi.org/10.1146/annurev. immunol.25.022106.141609.
3. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70:7788-99; PMID:20924102; http://dx.doi. org/10.1158/0008-5472.CAN-10-1736.
4. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-86; PMID:22174368; http://dx.doi. org/10.1158/0008-5472.CAN-11-1792.
5. Li X, Kostareli E, Suffner J, Garbi N, Hämmerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 2010; 40:3325-35; PMID:21072887; http://dx.doi. org/10.1002/eji.201041093.
6. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176:1582-7; PMID:16424187.
7. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010; 70:7800-9; PMID:20924111; http://dx.doi.org/10.1158/0008-5472.CAN-10-1681.
8. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N, et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010; 70:2665-74; PMID:20332236; http://dx.doi.org/10.1158/0008-5472.CAN-09-1574.
9. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011; 108:16723-8; PMID:21933959; http://dx.doi.org/10.1073/pnas.1110814108.
10. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011; 60:1137-46; PMID:21465316; http://dx.doi.org/10.1007/s00262-011-1011-9.
11. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx.doi.org/10.1038/nature10755.
12. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T, cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8:191-7; PMID:17136045; http://dx.doi.org/10.1038/ni1428.
13. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007; 204:57-63; PMID:17200412; http://dx.doi. org/10.1084/jem.20061852.
14. Suffner J, Hochweller K, Kühnle MC, Li X, Kroczek RA, Garbi N, et al. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3. LuciDTR mice. J Immunol 2010; 184:1810-20; PMID:20083650; http://dx.doi.org/10.4049/jimmunol. 0902420.
15. Riond J, Rodriguez S, Nicolau ML, Al Saati T, Gairin JE. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun 2009; 9:10; PMID:19877577.
16. Singh V, Ji Q, Feigenbaum L, Leighty RM, Hurwitz AA. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J Immunother 2009; 32:129-39; PMID:19238011; http://dx.doi. org/10.1097/CJI.0b013e31819144d7.
17. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198:569-80; PMID:12925674; http://dx.doi. org/10.1084/jem.20030590.
18. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID:10430624; http://dx.doi. org/10.1084/jem.190.3.355.
19. Teng MW, Ritchie DS, Neeson P, Smyth MJ. Biology and clinical observations of regulatory T cells in cancer immunology. Curr Top Microbiol Immunol 2011; 344:61-95; PMID:20512555; http://dx.doi. org/10.1007/82_2010_50.
20. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001; 194:481-9; PMID:11514604; http://dx.doi.org/10.1084/jem.194.4.481.
21. Zhang P, Côté AL, de Vries VC, Usherwood EJ, Turk MJ. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 2007; 67:6468-76; PMID:17616708; http://dx.doi.org/10.1158/0008-5472.CAN-07-1264.
22. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205.
23. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx.doi.org/10.1016/j. immuni.2009.04.010.
24. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-51; PMID:21430066; http://dx.doi.org/10.1158/0008-5472.CAN-11-0096.
25. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71:4809-20; PMID:21646474; http://dx.doi.org/10.1158/0008-5472.CAN-11-0753.